1. Scrip
  2. >>New Products

With Aduhelm Out Of The Gate, Biogen Focuses On Clearing Commercial Bottlenecks

 
• By Jessica Merrill

PET scans and CSF testing to confirm the presence of amyloid beta, and reimbursement, are expected to be early hurdles for launching aducanumab in Alzheimer's.

Traffic Jam
Biogen aims to clear obstacles to a smooth Aduhelm launch • Source: Alamy

Biogen, Inc. and Eisai Co., Ltd.'s Aduhelm (aducanumab) for Alzheimer's disease is expected to become a mega blockbuster drug, but early obstacles to diagnosis and reimbursement could slow the initial launch. During an investor call on 8 June, Biogen's management forecast modest revenue coming from Aduhelm in 2021, with a broader commercial ramp starting in 2022.

The drug, which received accelerated approval from the US Food and Drug Administration on 7 June, will be available within two weeks

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.